Phase III Randomized, Placebo-Controlled, Crossover Study of Soy Protein Isolate for Hereditary Hemorrhagic Telangiectasia
Hereditary Hemorrhagic Telangiectasia
About this trial
This is an interventional treatment trial for Hereditary Hemorrhagic Telangiectasia focused on measuring genetic diseases and dysmorphic syndromes, hematologic disorders, hereditary hemorrhagic telangiectasia, rare disease
Eligibility Criteria
Hereditary hemorrhagic telangiectasia (HHT) with 2 of the following: First-degree relative with HHT History of recurrent epistaxis or gastrointestinal bleeding Three or more skin telangiectasia Migraine headache meeting International Headache Society criteria 3 or more times a month for more than 1 year No pattern of daily headaches No severe head trauma No onset of headaches after 50 years of age At least 1 month since migraine prophylaxis At least 1 month since any of the following medications: Beta blockers; Calcium channel blockers; Divalproex sodium; Tricyclic antidepressants; Selective serotonin re-uptake inhibitors Concurrent regular treatment for migraine and gastrointestinal hemorrhage allowed Creatinine no greater than 2.5 g/dL No allergy to soy No pregnant women No women with intent to become pregnant